10. Haematology II: Leukaemia & Lymphomas Flashcards

1
Q

LOs

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

1.
what is leukaemia?

2.
what does it result in?

A

1
- Malignant neoplasms of haemopoietic stem cells

2
- Result in diffuse replacement of bone marrow and normal blood precursor cells by neoplastic cells

  • Bone marrow failure leads to anaemia, neutropenia and thrombocytopenia
  • Leukaemic cells spill over into blood and may infiltrate organs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how leukaemias classified?

A

classified based on cell type involved and its maturity:

  1. cell type
  2. maturity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the classes of leukaemia split into?

A
  • Cell type
    ~ Myeloid cell line
    ~ Lymphoid cell line
  • Maturity
    ~ Acute > 50% myeloblasts or lymphoblasts in
    bone marrow at clinical presentation
    ~ Chronic cells are more differentiated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

myeloid cell line?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

lymphoid cell line?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how are leukaemias diagnosed?

A
  1. BLOOD FILM
    ~ Suggests diagnosis
    ~ Due to presence of Abnormal WCC (white cells)
    ~ Presence of blasts
  2. BONE MARROW
    ~ usually confirms diagnosis
    ~ Hypercellular
    ~ Numerous blast cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what can blood film test and bone marrow aspirate tell us?

A
  • Important prognostic indicators
    ~ Leukaemia type
    ~ Cell phenotype
    ~ Chromosomal abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

aetiology of leukaemias

A
  • Ionizing radiation
  • Chemicals including benzene and alkylating agents
  • Viruses (e.g.. HTLV – human T-cell leukaemic virus)
  • Genetic factors (e.g.. Down’s syndrome)
  • Acquired haematological disorders such as aplastic anaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what can bone marrow infiltration result in?

A
  • can result in failure of other important cell lines
  • this can result in:
    ~ anaemias
    ~ impacted immune system
    ~ impact coagulation and platelet function
  • these over all can thus then cause:
  • pallor
  • malaise
  • fever + infection
  • bleeding
  • bruising / petechiae
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  1. why may tissue infiltration occur?
  2. what can tissue infiltration result in/ cause?
A

1
- neoplastic cells may spill out of the bone marrow into the peripheral blood
- this can lead to infiltration of other organs

2
- Lymphadenopathy
- Hepatosplenomegaly
- Central nervous system

  • Bone and joint pain (ALL)
  • Testicular swelling (ALL)
  • Gingival hypertrophy (AML) (important for dentistry)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

names of acute and chronic leukaemias?

A

ACUTE (immature cell lines) (could be myeloid or lymphoid depending on type of cell)
- Myeloid (AML = acute myeloid leukaemia)
- Lymphoid (ALL = acute lymphoblastic leukaemia)

CHRONIC (typically more mature cells)
- Myeloid (CML = chronic myeloid leukaemia)
- Lymphoid (CLL = chronic lymphocytic leukaemia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ALL - Acute lymphoblastic leukaemia

1
age of peak incidence

2
management

A

1
Children - peak incidence 4-5 years

2
- Remission induced with non-myelosuppressive chemotherapy
- 2-12 years >60% cure rate with chemotherapy
- Adults 20% cure rate
- Combination chemotherapy to induce remission
- CNS treatment performed prophylactically
- Maintenance therapy for up to 2 years increases disease-free survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AML - Acute myeloid leukaemia

1
incidence at what age most likely?

2
management?

A

1
- Most common leukaemia in adults
- Increasing incidence with age
- X400 higher incidence in children with Down’s syndrome

2 Management
- >80% cure rate with intensive chemotherapy in young patients
- 15% resistant disease
- 4-5 courses of intensive chemotherapy (each lasting 5-10 days)
- No maintenance therapy
- Autologous and allogenic stem cell transplant (if fail chemotherapy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

CLL - Chronic lymphocytic leukaemia

1
common age?
Male : female incidence?

2
clinical features

A

1
- 25 % of all leukaemias
- Elderly (>60years)
- M:F ~ 2:1

2
- Constitutional symptoms
- Lymphadenopathy
- Splenomegaly
- Recurrent infections
- Abnormal FBC (anaemia, thrombocytopenia)
- Hypogammaglobinaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

CLL - Chronic lymphocytic leukaemia

treatment?

A
  • Asymptomatic patients do not require treatment (monitoring only)
  • 30% of patients with early stage disease die of unrelated cause
  • Chemotherapy typically effective
  • Median survival 10-12 years
  • Mortality usually due to infection or bone marrow failure
  • Bone marrow transplantation occasionally attempted in younger patients with poor prognostic disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

CML - Chronic myeloid leukaemia

1
median onset age?
more common in M or F?

2
clinical features

A

1
- < 20% of all leukaemias
- Median age of onset 40-50 years
- Slight male predominance
- Chronic phase for years – no treatment
- Accelerated phase and then blast crisis - require treatment

2
- Bone marrow failure (anaemia, thrombocytopenia)
- Hypermetabolism (anorexia, weight loss, night sweats)
- Splenomegaly
- Leucostasis (visual disturbances, priapism)
- Hyperuricaemia (gout, renal failure)

18
Q

CML - Chronic myeloid leukaemia

what is philadelphia chromosome?
what did it lead to?

A
  • > 90% have ‘Philadelphia chromosome’
  • ‘Balanced translocation’ between 9 and 22
  • Resultant oncogene with tyrosine kinase activity
  • Lead to first targeted therapy for leukaemia – imatinib (tyrosine kinase inhibitor)
19
Q

classifications of lymphomas

A
  1. Hodgkin’s disease
  2. non-Hodgkin’s disease
20
Q

features of Hodgkin’s disease lymphomas

A
  • Nodal (involves lymph nodes)
  • Contiguous (applies to serial lymph nodes)
  • Good outcome
  • Not associated with immunodeficiency
21
Q

features of non-Hodgkin’s disease lymphomas?

A
  • Extranodal
  • Non-contiguous
  • Variable outcome
  • Associated with immunodeficiency
22
Q

Hodgkin’s disease lymphomas

1
peak incidence age?

2
annual incidence (M + F)?

3
aetiology?

A

1
- Peak incidence in third decade
- Possible bimodal age with second peak adults> 60yrs)

2
Annual incidence
Male - 3 per 100,000
Female - 1.8 per 100,000

3
Aetiology unknown
EBV (infectious mononucleosis) suggested

23
Q

Hodgkin’s disease lymphomas clinical features?

A
  • Lymphadenopathy
    (particularly cervical lymph chain)
    ~ Cervical and contiguous
    ~ Painless, non-tender, rubbery
    ~ Alcohol induced pain
  • Constitutional ‘B’ symptoms
    ~ Fever
    ~ Night sweats
    ~ Weight loss >10% in 6 month period
  • Anorexia and fatigue
  • Pruritus and erythematous rash
  • Mediastinal lymph node involvement
    ~ Hilar lymphadenopathy
    ~ Bronchial compression
    ~ SVC obstruction
  • Hepatosplenomegaly
24
Q

how is Hodgkin’s disease lymphomas staged?

A
  • staged based on Ann Arbor system
  • I Single LN region
  • II Two LN regions
  • III Groups on both sides of
    diaphragm
  • IV Widespread disease outside
    lymphatic tissues
  • B symptoms
    ~ Weight loss
    ~ Night sweats
    ~ Unexplained fever
25
Q

Hodgkin’s disease lymphomas management?

1
investigations

2
treatment

A

1
- FBC (full blood count) (normochromic normocytic anaemia)

  • Elevated ESR (inflam markers)
  • LFTs / U&Es / bone profile / LDH (liver+renal blood test)
  • CXR / CT
  • Lymph node biopsy (Reed-Sternberg cells presence?)
  • Rarely bone marrow examination

2
treatment (curative)

  • Early stage disease (IA/IIA)
    ~ Chemotherapy + radiotherapy
  • Advanced stage disease
    ~ Combination chemotherapy
    ~ Complete remission 60-90%
  • Prognosis is relative to stage of disease
  • 90% Stage I (5 year survival)
  • B symptoms presence worsens prognosis
26
Q

Non-Hodgkin’s disease lymphomas

1
presentation?

2
incidence in pop?

3
age?

4
male or female more common?

A

1
- Varied presentation

  • Heterogeneous group of disorders

2
Annual incidence 11 per 100,000

3
Slight male preponderance

4
Increases with age - rare < 40 years

27
Q

aetiology of Non-Hodgkin’s disease lymphomas

A
  • Immunodeficiency (acquired + congenital)
  • Infections
  • Ionizing radiation
  • Carcinogenic chemicals
  • Inherited disorders affecting DNA damage and repair
28
Q

Non-Hodgkin’s disease lymphomas

clinical features

A
  • Generalised lymphadenopathy
  • Oropharyngeal involvement (Waldeyer’s ring)
  • Bone marrow infiltration
    ~ Anaemia
    ~ Recurrent infections
    ~ Haemorrhage
29
Q

Non-Hodgkin’s disease lymphomas

management?

A
  • based on grade of disease
  • LOW GRADE DISEASE
    ~ May be asymptomatic requiring no treatment
    ~ Intermittent oral chemotherapy
  • HIGH GRADE DISEASE
    ~ Combination chemotherapy ~ 30% cure
30
Q

Multiple myeloma

1
what/ cause?

2
age range?

A

1
- Arises from malignant transformation of terminally differentiated B cell (plasma cell)

  • Monoclonal expansion results in secretion monoclonal Ig or light chains (paraproteins)
  • Typically long asymptomatic phase that can last for many years (MGUS – monoclonal gammopathy of undetermined significance)

2
- Most patients are between 40-80yrs old

31
Q

Multiple myeloma

clinical features?

A
  • Bone destruction
    ~ Myeloma cells stimulate osteoclasts causing
    bone destruction and classic well-defined
    osteolytic lesions and raised serum Ca2+
  • Bone marrow failure
    ~ Marrow infiltration leads to anaemia,
    thrombocytopenia and neutropenia and
    recurrent infections
  • Renal failure
    ~ Due to deposition and accumulation of
    paraproteins
  • Hyperviscosity syndrome
    ~ Headache and dizziness
  • Amyloidosis (development of abnormal protein cells - deposit in various tissues + infiltrate organs around body)
32
Q

Multiple myeloma

1
investigations?

2
Management?

A

1
- FBC = bone marrow failure
- Raised ESR and Ca2+
- U&Es demonstrate renal damage
- Protein electrophoresis demonstrates monoclonal paraprotein
- Bence-Jones proteins in urine

2
- Only if evidence of organ damage
- Chemotherapy if evidence bone marrow failure or bone lesions
- Most patients respond however relapse if common
- Radiotherapy useful if bone pain

33
Q

DENTAL RELEVANCE OF LEUKAEMIAS + LYMPHOMAS

  • oral manifestations may result as secondary to the underlying process
A
  • Secondary
    ~ Manifestations anaemia
    ~ Haemorrhagic tendency
    ~ Increased susceptibility to infection
    ~ Neutropenic ulceration
34
Q

DENTAL RELEVANCE OF LEUKAEMIAS + LYMPHOMAS

Leukaemic infiltration?

A
  • in some patients leukaemic cells spill out of bone marrow and deposit in various tissues
  • this can include gingiva + bone
  • Typically gingival however also bone infiltration
  • 3.6% of dentate patients

-c18.5% in AML

  • Friable and haemorrhagic
  • Increased tooth mobility
35
Q

DENTAL RELEVANCE OF LEUKAEMIAS + LYMPHOMAS

1
Intraoral lymphomas

2
management

A
  • can develop intraorally
  • Typically non-Hodgkin lymphomas (NHL) associated with HIV
  • Most commonly affected sites are the fauces and gingivae
  • Typically present as rapidly enlarging masses with bone destruction

2
- Chemotherapy

  • Radiotherapy
36
Q

DENTAL RELEVANCE OF LEUKAEMIAS + LYMPHOMAS

treatment of conditions can lead to oral complications

A
  • Mouth care can be overlooked
  • Oral complications
    ~ 90% of children
    ~ 50% of adults
  • Mucositis (damage to lining of mouth)
  • Infection including candidosis and viral (HSV, VZV)
  • Mucosal bleeding
  • Xerostomia
37
Q

DENTAL RELEVANCE OF LEUKAEMIAS + LYMPHOMAS

Mucositis

1
associated with what radiotherapy + chemotherapy agents

2
- onset/ how to stope?
- what is severity of mucositis related to?

A

1
- Associated with number of chemotherapy agents and radiotherapy
- 5-fluorouracil
- Methotrexate
- Bleomycin
- Daunorubicin
- Doxorubicin

2-
- Rapid onset and good recovery following cessation of chemotherapy
- Severity related to white cell depletion
- Increases risk of infection and may limit chemotherapy

38
Q

DENTAL RELEVANCE

Radiotherapy common complications

A
  • Mucositis
  • Xerostomia
  • Caries
  • Candidosis
  • Loss of taste
  • Trismus
  • Osteoradionecrosis and osteomyelitis
39
Q

DENTAL RELEVANCE

1
oral care before radiotherapy

2
oral care following radiotherapy

A

1
- Assessment and treatment dental disease
- Meticulous oral hygiene and preventative care
- Minimum 2 week interval between extracting and commencing radiotherapy (no bone should be left exposed)

2
- Reinforcement of oral hygiene and preventive dental care
- Palliation for dry mouth
- Dental extractions
~ Minimal trauma with careful suturing
~ Prophylactic antibiotics

40
Q

Haematopoietic stem cell transplant (HSCT)

A
41
Q

Graft vs host disease

A
  • Serious complication of allogenic HSCT
  • Divided into acute and chronic GvHD based on clinical findings
  • Oral cGvHD most of most common presentations
  • Characterised by lichenoid inflammation - particularly on the tongue and buccal mucosa
  • Salivary glands may also be involved with hypofunction (major glands) and recurrent mucoceles (minor glands)

MANAGEMENT
- Lichenoid treated with topical steroids
- Xerostomia treated in same way as any other cause